Testosterone, thrombophilia, thrombosis

Freedman, Joel; Glueck, Charles J.; Prince, Marloe; Riaz, Rashid; Wang, Ping

doi:10.1016/j.trsl.2014.12.003

Cited by 38 publications

(49 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, because all the individuals in the VTE groups were found to have previously undiagnosed thrombophilia and because the studies did not include control groups of nontestosterone users with comparable rates of underlying thrombophilia, it was not possible to determine the extent to which VTE was associated with testosterone use versus underlying thrombophilia or to examine the interaction between testosterone therapy and thrombophilia. In addition, a recent study by Friedman et al 24 reported that testosterone therapy interacted with thrombophilia to increase the risk of VTE. The design of this cross-sectional studydwhich relied on 4 convenience samples of patientsddid not allow a statistical analysis of an interaction effect between testosterone therapy and underlying thrombophilia leading to VTE.…”

Section: Discussionmentioning

confidence: 99%

Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy

Baillargeon

Urban

Morgentaler

et al. 2015

Mayo Clinic Proceedings

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy

Baillargeon

Urban

Morgentaler

et al. 2015

Mayo Clinic Proceedings

Self Cite

View full text Add to dashboard Cite

“…Therefore, they interact with all parts of the hemostatic system. We also used age and sex as matching parameters although there was no correlation in univariate analysis, because advanced age ([60 years) has been shown as an independent risk factor of venous thromboembolism in previous studies [11,12], and some reports suggest that sex hormones affect thrombosis [13,14].…”

Section: Discussionmentioning

confidence: 99%

Portomesenteric vein thrombosis after gastric surgery

et al. 2015

View full text Add to dashboard Cite

Background Postoperative portomesenteric venous thrombosis (PMVT) is a rare but potentially serious complication of gastric surgery. This study analyzed the incidence, characteristics, risk factors, and outcomes of PMVT following gastric surgery. Methods Medical records of patients who underwent gastric surgery between January 2007 and December 2012 were reviewed retrospectively. The risk factors of PMVT were analyzed by a logistic regression analysis with control group matched 1:4 by age, sex, and cancer stage and by a Poisson regression analysis with unmatched control group. The resolution rate of PMVT in 12 months was compared between the treatment group and the nontreatment group. Results The total incidence of PMVT after gastric surgery was 0.67 % (31/4611). Most (54.84 %) PMVT cases were detected within 1 month postoperatively. No accompanying deep vein thrombosis (DVT) was noted. Multivariate comparison with 1:4 matched control showed that combined splenectomy, synchronous malignancy, and intra-abdominal complication were independent risk factors. Advanced stage, combined splenectomy, and synchronous malignancy were independent risk factors in Poisson regression analysis using unmatched controls. The resolution rate of PMVT was not different from patients treated with anticoagulation (n = 6) or antiplatelet therapy (n = 1) and were not significantly different with those of the untreated group [85.7 % (6/7) vs. 82.3 % (14/17), p = 0.935] during 1-year follow up. Conclusions PMVT after gastric surgery was associated with advanced cancer stage, combined splenectomy, and synchronous malignancy, but it was not related to laparoscopy or DVT. Significant differences in the natural course of PMVT were not found between the treatment group and observation group.

show abstract

“…Based on several case reports, it was theorized that one of the serious side effects of T therapy is increased risk of venous thromboembolism (VTE) due to increased hematocrit seen in some men receiving T treatment attributed to testosterone's ability to stimulate erythropoiesis (16). This concern became less theoretical when the FDA required pharmaceutical companies to add a warning to their products regarding the risk of VTE.…”

Section: T Therapy and Increased Risk Of Venous Thromboembolismmentioning

confidence: 99%

Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined?

Traish

2016

American Journal of Physiology-Regulatory, Integrative and Comp

View full text Add to dashboard Cite

In the adult male, testosterone (T) deficiency (TD) also known as male hypogonadism, is a well-established medical condition, which has been recognized for more than a century. T therapy in men with TD was introduced as early as 1940s and was reported to improve overall health with no concomitant serious adverse effects. A wealth of recent studies demonstrated that T therapy in men with TD is associated with increased lean body mass, reduced fat mass and waist circumference, improvement in glycemic control, and reduced obesity. T therapy is also associated with improvements in lipid profiles, amelioration of metabolic syndrome (Met S) components, reduced inflammatory biomarkers, reduced systolic and diastolic blood pressure, and improvements in sexual function. More importantly, T therapy is associated with amelioration of diabetes and reduced mortality. However, few studies, marred with serious methodological and analytical flaws reported between 2010 and 2014, suggested that T therapy is associated with increased cardiovascular (CV) risk. As summarized in this review, a thorough and critical analysis of these studies showed that the risks purported are unsubstantiated and such studies lacked credible scientific and clinical evidence. Moreover, recent observational, registry studies, clinical trials, and meta-analyses, all revealed no increase in CV risks in men receiving T therapy. In this review, the benefits of T therapy in adult men with TD and the lack of credible evidence suggesting that T therapy is linked to increased CV risks are discussed. It should be noted that the literature is replete with studies demonstrating beneficial effects of T therapy on CV and overall health.

show abstract

Testosterone, thrombophilia, thrombosis

Cited by 38 publications

References 60 publications

Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy

Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy

Portomesenteric vein thrombosis after gastric surgery

Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined?

Contact Info

Product

Resources

About